Provided herein are dUTPase inhibitors, compositions comprising such compounds and methods of using such compounds and compositions.

Provided herein are dUTPase inhibitors, compositions comprising such compounds and methods of using such compounds and compositions.

Provided are compounds that inhibit ferroptosis activity, or modulate or inhibit a disease associated with ferroptosis dysregulation, such as neuropathy, ischemia reperfusion injury, acute kidney failure and cancer, including corresponding sulfonamides, and pharmaceutically acceptable salts, hydrates and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof with an effective amount of the compound or composition, and detecting a resultant improvement in the person's health or condition.

The invention relates to the field of pesticide technology, and in particular a type of carboxylic acid derivative-substituted iminoaryl compound, preparation method, herbicidal composition and use thereof. The compound, as shown in general formula I:

##STR00001## wherein, Q represents

##STR00002##

Y represents halogen, haloalkyl or cyano; Z represents halogen; M represents CH or N; W represents OX.sub.5, SX.sub.5 or N(X.sub.5).sub.2; X represents —CX.sub.1X.sub.2-(alkyl).sub.n-, -alkyl-CX.sub.1X.sub.2-(alkyl).sub.n- or —(CH.sub.2).sub.r—; X.sub.3 and X.sub.4 each independently represent O, S, NH or N-alkyl, etc. The compound has excellent herbicidal activity against gramineous weeds, broadleaf weeds, cyperaceae weeds and so on even at low application rates, and has high selectivity for crops.

The invention relates to the field of pesticide technology, and in particular a type of carboxylic acid derivative-substituted iminoaryl compound, preparation method, herbicidal composition and use thereof. The compound, as shown in general formula I:

##STR00001## wherein, Q represents

##STR00002##

Y represents halogen, haloalkyl or cyano; Z represents halogen; M represents CH or N; W represents OX.sub.5, SX.sub.5 or N(X.sub.5).sub.2; X represents —CX.sub.1X.sub.2-(alkyl).sub.n-, -alkyl-CX.sub.1X.sub.2-(alkyl).sub.n- or —(CH.sub.2).sub.r—; X.sub.3 and X.sub.4 each independently represent O, S, NH or N-alkyl, etc. The compound has excellent herbicidal activity against gramineous weeds, broadleaf weeds, cyperaceae weeds and so on even at low application rates, and has high selectivity for crops.

Methods of treating malaria comprising administration of compounds of Formula (I′) or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the variables are as defined herein. It also provides uses of the compounds of Formula (I), as defined herein, for inhibiting plasmepsin X, plasmepsin IX or plasmepsin X and IX activity, for treating a Plasmodium infection, and for treating malaria. Also provided are methods of treatment further comprising administration of one or more additional anti-malarial compounds.

##STR00001##

Methods of treating malaria comprising administration of compounds of Formula (I′) or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the variables are as defined herein. It also provides uses of the compounds of Formula (I), as defined herein, for inhibiting plasmepsin X, plasmepsin IX or plasmepsin X and IX activity, for treating a Plasmodium infection, and for treating malaria. Also provided are methods of treatment further comprising administration of one or more additional anti-malarial compounds.

##STR00001##

The present technology provides an isolated compound of Formula I, compositions including such compounds, methods of inhibiting TGF-β signaling and/or TGF-β induced epithelial mesenchymal transitions (EMT), and treating certain cancers involving TGF-β signaling and/or EMT.

The present technology provides an isolated compound of Formula I, compositions including such compounds, methods of inhibiting TGF-β signaling and/or TGF-β induced epithelial mesenchymal transitions (EMT), and treating certain cancers involving TGF-β signaling and/or EMT.

Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for the inhibition of Signal Transducer and Activator of Transcription 5a and 5b (STAT5). Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as, for example, breast cancer and pancreatic cancer.